Conclusions There is currently much experimental evidence that ROS-induced oxidative damage is a common denominator of many chronic diseases, especially those whose incidence is typical for advanced age, such as cancer, cardiovascular disease, and neurological disorders
In three trials, LEADER, SUSTAIN 6, and REWIND, the GLP-1RA was superior to placebo ( p = .01, p = .02, and p = .026, respectively, for superiority), showing lower risk of the composite MACE endpoint: liraglutide hazard ratio (HR) 0.87 (95% confidence interval [CI]: 0.780.97), sc semaglutide HR 0.74 (95% CI: 0.580.95), and dulaglutide HR 0.88 (95% CI: 0.790.99) (Figure 1)
How common are gastrointestinal side effects across the class
Gently swirl to dissolveavoid shaking to maintain peptide structure